 SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 GLOBE NEWSWIRE -- RAPT Therapeutics, Inc. Nasdaq: RAPT, a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September: 